Immunwork, Inc., founded in 2014, was a subsidiary of T-E Pharma Holding, focused on the development of innovative platforms and novel drugs. Utilizing the fatty acid bundle platform, we have developed the ultra-long-acting drug candidates for the treatment of critical endocrine diseases, such as diabetes, obesity, acromegaly and neuroendocrine tumors. Two promising candidates are currently in the human clinical trial stage.
Another affiliated company, the sister company of Immunwork – T-E Meds, Inc., was established in 2022. It focused on the development of antibody-derived drug candidates by the innovative antibody-drug conjugate (ADC) or antibody-radionuclide conjugate (ARC) platforms. These potential drugs are intended for the treatment of various lethal cancers, including multiple myeloma and pancreatic cancer.
T-E Meds website: https://www.temeds.com/
